Below are the most recent publications written about "Benzoxazines" by people in Profiles.
-
Diphoko T, Gaseitsiwe S, Kasvosve I, Moyo S, Okatch H, Musonda R, Wainberg M, Makhema J, Marlink R, Novitsky V, Essex M. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. AIDS Res Hum Retroviruses. 2018 08; 34(8):667-671.
-
Reyes BA, Szot P, Sikkema C, Cathel AM, Kirby LG, Van Bockstaele EJ. Stress-induced sensitization of cortical adrenergic receptors following a history of cannabinoid exposure. Exp Neurol. 2012 Aug; 236(2):327-35.
-
Carvalho AF, Van Bockstaele EJ. Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion. Neurosci Lett. 2011 Aug 1; 500(1):82-5.
-
Carvalho AF, Reyes AR, Sterling RC, Unterwald E, Van Bockstaele EJ. Contribution of limbic norepinephrine to cannabinoid-induced aversion. Psychopharmacology (Berl). 2010 Sep; 211(4):479-91.
-
Carvalho AF, Mackie K, Van Bockstaele EJ. Cannabinoid modulation of limbic forebrain noradrenergic circuitry. Eur J Neurosci. 2010 Jan; 31(2):286-301.
-
Reyes BA, Rosario JC, Piana PM, Van Bockstaele EJ. Cannabinoid modulation of cortical adrenergic receptors and transporters. J Neurosci Res. 2009 Dec; 87(16):3671-8.
-
Fox KM, Sterling RC, Van Bockstaele EJ. Cannabinoids and novelty investigation: influence of age and duration of exposure. Behav Brain Res. 2009 Jan 23; 196(2):248-53.
-
van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials. 2008 Sep-Oct; 9(5):324-36.
-
Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008 Aug 12; 52(7):569-76.
-
Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S, Squires K. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials. 2008 Jan-Feb; 9(1):11-25.